Skip to main content
SpringerLink
Log in

The preemptive use of factor VIIa is associated with lower costs than intraoperative use during liver transplantation

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Scheffert JL, Weimert NA, Taber DJ, Patel N, Dunn BD, Cattanach LA, Bratton CF, McGillicuddy JW, Lin A, Hughes MG, Chavin KD, Baliga PK.Economic and clinical outcomes analysis comparing preemptive versus intraoperative factor VIIa administration during orthotopic liver transplantation. American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST): 386-387 abstr. 667, 30 May 2009. Available from: URL: http://www.atcmeeting.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The preemptive use of factor VIIa is associated with lower costs than intraoperative use during liver transplantation. Pharmacoecon. Outcomes News 581, 7 (2009). https://doi.org/10.2165/00151234-200905810-00020

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905810-00020

Keywords

Search

Navigation